700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|Kevser Erol, Cigdem Cengelli Unel and Sule Aydin|
|Eskisehir Osmangazi University, Turkey|
|Posters & Accepted Abstracts: Clin Exp Pharmacol|
|Objective: Cisplatin is a widely used antineoplastic drug in the treatment of malignancies. Cannabinoids have shown analgesic features in neuropathic pain models. Agmatine has also been shown to relieve neuropathic pain in different animal models. The aim of this study was to investigate the in vitro effects of anandamide, a cannabinoid receptor agonist and agmatine on cisplatin-induced neurotoxicity on primary dorsal root ganglia. Materials & Methods: Primary cultures of DRG were also prepared from 1-day old rats. The toxic effects of cisplatin were evaluated by incubating the cells with cisplatin (50-500 μm). Concentration of 200 μm of cisplatin which showed submaximal neurotoxicity was used alone and with 10-500 μm concentration of agmatine or with anandamide (10-1000 μm) for determining its possible neuroprotective activity. MTT assay was used to detect the toxicity of DRG cells. Results were evaluated by using ELISA test system at a wavelength of 450 nm. Results: Cisplatin had concentration-dependent neurotoxic effects on DRG in vitro and high concentration of anandamide attenuated cisplatin neurotoxicity. But agmatine could not alter the neurotoxic effect of cisplatin. Conclusions: We suggest that exogenous cannabinoid may represent a promising new protective strategy against cisplatin neurotoxicity.|
Kevser Erol has completed her PhD from Dicle University and Postdoctoral studies from Anadolu University, School of Medicine. She is the Director of Department of Pharmacology and has published more than 125 papers in reputed journals.
Email: [email protected]
|PDF | HTML|